A Study of 99mTc-MIP-1404 and 99mTc-MIP-1405 in Patients With Metastatic Prostate Adenocarcinoma and Healthy Volunteers

This trial is a single-blind, randomized, cross-over design. Up to six patients with
confirmed metastatic prostate adenocarcinoma; six newly diagnosed, high-risk patients with
prostate adenocarcinoma; and up to six healthy volunteers will receive 20.0 (± 3) mCi of
intravenously administered 99mTc MIP 1404 or 99mTc MIP 1405. Whole-body planar scintigraphic
images will be acquired at various times post-injection over 24 hours. A pelvic SPECT/CT
image will be acquired on the first day. Blood and urine will be collected for
pharmacokinetic measurements and metabolic analysis over 24 hours. Each patient will receive
an initial study drug administration and a second study drug administration approximately 14
to 21 days after the first. A final follow-up visit will occur approximately 2-3 weeks after
the second study drug.

Inclusion Criteria:

Participants must meet all of the following criteria to be enrolled in this study.

1. Male aged 21 years or older.

2. Ability to provide signed informed consent and willingness to comply with protocol
requirements.

3. Participants must agree to use condoms for a period of seven days after each
injection, if engaged in sexual activity.

Additional Inclusion Criteria for Patients:

i. Histologic diagnosis of prostate cancer by validated medical history. (Pathology
report, if available).

ii. Evidence of metastatic disease demonstrated by a documented abnormal bone scan, CT
scan, or MRI plus a Clinical Stage 3 and Gleason Score ≥ 8.

iii. Karnofsky performance is ≥ 60.

Additional Inclusion Criteria for Healthy Volunteers:

i. PSA laboratory assessment within normal range (PSA < 4 ng/ml). ii. Normal findings on a
digital rectal examination. iii. Hemoglobin and hematocrit within normal range.

Exclusion Criteria:

Participants must NOT meet any of the following criteria to be enrolled in this study.

1. Received an investigational compound and/or medical device or is part of an
investigational study within the past 30 days before enrollment into this study.

2. Subject was administered a radioisotope within 5 physical half lives of that
radioisotope prior to study enrollment

3. Have any medical condition or other circumstances which, in the opinion of the
Investigator, would significantly decrease the chances of obtaining reliable data,
achieving study objectives, or completing the study and/or post dose follow-up
examinations.

4. Participant is determined by the Investigator to be clinically unsuitable for the
study.

5. Serum creatinine ≥ 2.0 mg/dl

6. Total bilirubin ≥ 2.0 mg/dl

7. Liver transaminases ≥ 1.5 x ULN

8. Platelet count < 150,000/mm3

9. Absolute neutrophil count (ANC) < 2,000/mm3.

10. Hematocrit < 30% or hemoglobin < 10 g/dl.

11. Abnormal coagulation profile (PT, PTT or INR) > 1.3 ULN unless on therapeutic
anticoagulation.

Additional Exclusion Criteria for Patients:

Patients will be excluded from the study if any of the following criteria are observed:

i. Androgen deprivation therapy or other forms of hormonal therapy not stable for a period
of 14 days prior to screening.

ii. Subject has received a permanent prostate brachytherapy implant within the last 3
months for 103Pd implants; or 12 months for 125I implants.

iii. Subject on or expected to be starting cytotoxic chemotherapy during the study period.

iv. Has had any other malignancies within the past year, other than basal or squamous cell
carcinoma of the skin, diagnosis and location must be defined or be defined as clinically
controlled or treated to complete response.

Additional Exclusion Criteria for Healthy Volunteers:

Healthy Volunteers will be excluded from the study if any of the following criteria are
observed:

i. Have had any malignancies within 5 years other than basal or squamous cell carcinoma of
the skin.

ii. History of known prostate adenocarcinoma, prostate surgery/biopsy, prostatitis and/or
symptoms suggestive of or associated with possible prostatitis within 6 months of
enrollment.